Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Tarsus Pharmaceuticals Inc TARS

Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing... see more

Recent & Breaking News (NDAQ:TARS)

Tarsus to Participate in Upcoming Investor Conference

GlobeNewswire November 24, 2025

Tarsus to Participate in Upcoming Investor Conference

GlobeNewswire November 5, 2025

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

GlobeNewswire November 4, 2025

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

GlobeNewswire October 28, 2025

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire August 27, 2025

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

GlobeNewswire August 6, 2025

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

GlobeNewswire July 30, 2025

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire May 29, 2025

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire May 8, 2025

Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

GlobeNewswire May 1, 2025

Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

GlobeNewswire April 24, 2025

Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting

GlobeNewswire April 22, 2025

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

GlobeNewswire March 12, 2025

Tarsus Announces Proposed $100.0 Million Public Offering

GlobeNewswire March 12, 2025

Tarsus to Participate in Upcoming Investor Conference

GlobeNewswire March 6, 2025

Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

GlobeNewswire February 25, 2025

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

GlobeNewswire February 20, 2025

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire January 30, 2025

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

GlobeNewswire January 13, 2025

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

GlobeNewswire November 13, 2024

Podcasts